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Abstract: Although atherosclerosis was previously thought to be mainly a degenerative disease, it is now well 
ascertained that its pathogenesis is inflammatory. This review describes the history of a new atherogenetic 
concept, including the pivotal role of apoE-knockout mice in understanding the inflammatory background  
of atherosclerosis. There has been lack of unequivocal evidence of an important inflammatory component  
in atherogenesis. This evidence was delivered by a new technique – gene targeting, for the invention of which 
Mario R. Capecchi, Martin J. Evans and Oliver Smithies received in 2007 the Nobel Prize in Physiology or 
Medicine. The pivotal stage of atherogenesis is the antigen presentation by macrophages to T lymphocytes.  
This antigen could be a fragment of oxidized low-density lipoproteins “digested” by macrophage, heat shock 
protein 60, β2-glycoprotein I or fragments of bacterial antigens. For interaction between the immunological cells  
a presence of CD40 receptor on macrophages and its ligand CD40L on the surface of T lymphocytes are 
necessary. During the interaction between these cells an immunological type T helper 1 (Th1 – cellular) or T 
helper 2 (Th2 – humoral) response arises. Th1 response and its mediators: interferon γ, tumor necrosis factor α, 
interleukin-1, interleukin-12 and interleukin-18 enhance atherogenesis, whereas Th2 response and its mediators: 
interleukin-4, interleukin-5, interleukin-10 and interleukin-13 inhibit the development of atherosclerosis. 
Atherosclerosis is therefore a chronic inflammatory disease, in most cases initiated by hypercholesterolemia. 
Nowadays, hypercholesterolemia and inflammation are considered as “partners in crime”. The concept of 
atherosclerosis as inflammatory disease is fairly new, however, it is already considered as an undisputable 
achievement of science which have particular therapeutic consequences.
Key words: atherogenesis, atherosclerosis, immunity, inflammation
INTRODUCTION
Studies concerning the pathogenesis of atherosclerosis en-
tered a new phase at the turn of the 21st century. The 20th 
century was the age of cholesterol and lipoproteins, which has 
been concluded in a number of clinical studies carried out on a 
large scale, and they demonstrated unequivocally that normal-
ization of hypercholesterolemia significantly decreased the in-
cidence and mortality of coronary artery disease [1,2]. Nearly 
to the end of the nineties, atherosclerosis had been assumed to 
develop as the so-called chronic response to injury (response-
to-injury hypothesis) that resulted in the loss of endothelial 
cells which line the inner side of the vessels [3]. However, oth-
er studies showed that the endothelial cells covering the early 
atheromatous changes were in reality intact [4]. 
Thus, atherosclerosis had been considered first of all a 
degenerative disease [5-7]. However, approximately 20 years 
ago, the trials started to focus to a large extent on another 
pathogenetic mechanism of atherosclerosis, not considered so 
far – the inflammatory process.
The first indications
In 1986, with the use of monoclonal antibodies, the small 
cells with round nucleus present in the atheromatous plaque, 
known before as “small monocytes”, were demonstrated to be 
T lymphocytes [8]. Several years later it was shown that these 
lymphocytes “recognize” as antigens the oxidized molecules of 
low-density lipoproteins (LDL) – oxLDL [9].
Moreover, the correlation between atherosclerosis and the 
presence of at least two types of infectious microorganisms; 
Chlamydia pneumoniae and herpes simplex virus was observed 
[10,11]. It raised the question if the inflammatory process 
participate in atherosclerosis. Speculations of this kind were 
initially received with great scepticism because there was no 
spectacular and unequivocal evidence of a significant role of 
inflammation in atherosclerosis. 
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This evidence was delivered by a new technique – gene 
targeting, for the invention of which Mario R. Capecchi (Italy), 
Martin J. Evans (United Kingdom) and Oliver Smithies (USA) 
received the Nobel Prize in Physiology or Medicine in 2007.
Additional evidence for the presence  
of inflammation in atherosclerosis
The newest model of atherosclerosis (described precisely at 
the end of the paper) enabled the investigators to create apoE-
knockout mice, an ideal animal model to test the influence of 
singular proteins participating in the inflammatory response 
on the development of atherosclerosis. These studies showed, 
for example, that the absence of only one cytokine – inter-
feron γ (IFN-γ), reduced atherosclerosis even by 60% [12]. 
The overexpression of adhesive molecules (vascular adhesion 
molecule 1 and intercellular adhesion molecule 1) at sites with 
atheromatous changes was also observed in apoE -knockout 
mice [13]. Monocyte chemotactic protein was shown to play 
an important part in the progression of atheromatous lesions 
[14,15]. Moreover, it was observed that interleukin-18 knock-
out decreased atherosclerosis by 35% [16,17].
Inhibition of CD40 signaling reduced atherosclerosis [18]. 
This was explained by the fact that ligation of CD40 molecule 
(tumor necrosis factor α [TNF-α] receptor superfamily mem-
ber) – found in the atheromatous plaque, on endothelial cells, 
vascular smooth muscle cells, antigen-presenting cells, plate-
lets – with CD40L activates a number of transcription factors: 
NF-κB, AP-1, STAT-1 or Egr-1. Therefore, it influences, for 
example, the endothelial cell, which, in consequence, acquires 
proinflammatory and proatherosclerotic phenotype leading to 
the expression of adhesive molecules and tissue factor on its 
surface. It creates new possibilities of therapeutic approach, 
consisting in inhibition of the CD40–CD40L pathway [19-21]. 
In mice the effect of CD40 is also antagonized by transform-
ing growth factor β [22].
Finally, in apoE-knockout mice with severe combined im-
munodeficiency (SCID) atherosclerosis was reduced by 70% in 
comparison to the control group, due to a significantly lower 
number of lymphocytes in mice with SCID. It was demon-
strated that transfer of T cells to these mice aggravated ath-
erosclerosis even by 164% [23].
Atherosclerosis as an inflammatory process
These and other facts made the investigators realize un-
equivocally that inflammation was essential for atherogenesis. 
Therefore, in 1999, just before his death, Russell Ross (the au-
thor of the previous theory of atherosclerosis as a chronic re-
sponse to injury) officially proclaimed that atherosclerosis was 
an inflammatory disease [24]. 
Whereas the deposition of atheromatous lipids and the 
accumulation of foam cells – macrophages filled with such 
lipids – in intima is the main morphological hallmark of ath-
erosclerosis, the more subtle changes in the environment of the 
arterial wall, stimulated by the influx of inflammatory cells 
and local release of cytokines and other inflammatory media-
tors are currently recognized as the crucial causative factors of 
atherogenesis [25,26].
Inflammation occurs in response to a factor that desta-
bilizes the local homeostasis. The factors that cause Toll-like 
receptor dependent macrophage activation in the arterial wall 
include oxLDL, heat shock protein 60 (HSP60) and bacterial 
toxins [27].
The first stage of atherogenesis consists in endothelial 
dysfunction [24]. It involves first of all the regions of arte-
rial bifurcations where the blood flow is not laminar. Hence, 
these localizations are prone to develop atherosclerosis. In such 
places LDL is stored in the subendothelial space. Low -density 
lipoprotein accumulation is increased if serum LDL level is el-
evated. Low -density lipoprotein is transported by passive dif-
fusion and its accumulation in the vascular wall seems to de-
pend on the interaction between apolipoprotein B of the LDL 
molecule and proteoglycans of the matrix [28]. 
There is evidence that unchanged LDL are “collected” by 
the macrophages too slowly to activate their transformation 
into foam cells. Therefore, it has been suggested that LDL 
molecule is “modified” in the vascular wall. The most signifi-
cant modification is lipid oxidation, resulting in the formation 
of so-called “minimally oxidized” LDL [29]. The generation of 
these “aliens” for the body molecules leads to the development 
of inflammatory response, with participation of monocytes 
and lymphocytes in the first place [30,31]. 
The inflammation is triggered by accumulation of the 
minimally oxidized LDLs in the subendothelial space, thus 
stimulating the endothelial cells to produce a number of 
proinflammatory molecules [32]. 
Before the “minimally oxidized” LDL have been phago-
cytised by the macrophages, they have to be modified into 
“highly oxidized” LDL. The scavenger receptors are respon-
sible for the rapid uptake of the modified LDL [33]. 
During the following phase macrophages “present the an-
tigen” to T lymphocytes. This antigen may be a fragment of 
oxidized LDL “digested” by the macrophages (Fig.), HSP60, 
β2-glycoprotein I or the fragments of bacterial antigens [34].
The interaction between the immunological cells requires 
the presence of CD40 receptor on the surface of macrophages 
and its ligand CD40L on the surface of T lymphocytes [35,36]. 
The reciprocal action of these cells produces the immunologi-
cal response of type T helper 1 (Th1 – cellular) or of type 
T helper 2 (Th2 – humoral). It is currently believed that the 
immunological response of Th1 type and its mediators: IFN-γ, 
TNF-α, interleukin-1, interleukin-12 as well as interleukin-18 
accelerate atherosclerosis, whereas the response of Th2 type 
and its mediators: interleukin-4, interleukin-5, interleukin-10 
as well as interleukin-13 inhibit the development of atheroscle-
rosis [37-39]. Therefore, there has arisen an idea of vaccination 
as a future treatment against atherogenesis [40].
The next phase of atherogenesis is the development of 
fibrous atheroma. The deposition of extracellular cholesterol 
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of C57BL/6J strain (wild type), which led to the formation of 
apoE-knockout, homozygous mice in the second generation 
[53]. The inactivation of the gene coding apoE resulted in 
the formation of mice with a phenotype with a complete sup-
pression of apoE, but with preservation of fertility and vital-
ity [54]. The apoE-knockout mice, in contrast to all of other 
animal models, develop atherosclerosis spontaneously, without 
high-cholesterol diet [55]. 
The generation of such a model changed the nature of the 
studies on the pathogenesis of atherosclerosis and enabled the 
investigators to formulate a new definition of atherosclerosis as 
a chronic inflammation [52]. 
SUMMARY
In a number of reports on atherogenesis published so far 
there has been a tendency to consider this process as the effect 
of dyslipidemia or inflammation alone. It is an erroneous di-
chotomy. It should be emphasized that atherosclerosis results 
from both lipid disorders and enhanced inflammation. 
Therefore, atherosclerosis is a chronic inflammatory dis-
ease, in most cases initiated and aggravated by hypercholes-
terolemia. In the review published in Nature Medicine hyperc-
holesterolemia and inflammation were described as “partners 
in crime” [56].
The inflammatory concept of atherosclerosis has been for-
mulated just in the recent years. However, it is currently an 
unquestionable achievement of science which also have specific 
therapeutic implications [57-62].
and its esters is then intensified as well as the migration of 
smooth muscle cells from media to intima, proliferation of 
these cells and finally production of the extracellular matrix 
by the smooth muscles cells.
A stable atheromatous plaque is most commonly covered 
with a fairly thick fibrous layer, protecting the lipid nucleus 
from contact with the blood. In an unstable plaque there is a 
big lipid nucleus with a fairly thin fibrous layer. In atheroma-
tous plaque, changed as described above, the proinflammatory 
factors produced by T lymphocytes (such as IFN-γ) seem to 
play a crucial role. They decrease production of the extracel-
lular matrix by smooth muscles and at the same time increase 
production of the metalloproteinases by macrophages [41].
Is atherosclerosis an autoimmunological 
disease?
The role of HSP60 as an initiator of atherogenesis is cur-
rently intensively investigated. Its “molecular mimicry” with 
HSP of Chlamydia has been observed [42]. Moreover, the 
anti-oxLDL antibodies resemble antiphospholipid antibodies, 
therefore the concept of atherosclerosis as an autoimmunologi-
cal disease has been established [34,43,44]. The investigators 
also emphasize a high pathogenetic similarity of atherosclero-
sis to rheumatoid arthritis [45].
The newest experimental model  
of atherosclerosis
Since 1992 the mouse has become an excellent object for 
the studies on atherosclerosis, replacing the previous animal 
models [46-48]. Then, the first line of mice with a switched-
off gene for apolipoprotein E (apoE-knockout) was developed 
almost contemporaneously in two laboratories in the United 
States [49,50]. These mice were soon described as “reliable 
and useful, the best animal model of atherosclerosis in present 
times” [51].
During the generation of apoE-knockout mice (known 
also as apoE null or apoE deficient mice) the normal gene 
coding apolipoprotein E is replaced by a mutated gene which 
does not produce this molecule. Such mice are called apoE-
knockout because they have a knockout, switched-off, null or 
inactivated gene coding apolipoprotein E. For clarity, in the 
following sections of this paper we will use the most popular 
name: apoE-knockout mice. 
The year 1992, in which apoE-knockout mice were in-
vented by a homological exchange of genes, was a real break-
through year in the studies on the pathogenesis of atheroscle-
rosis [52].
The apoE-knockout mice were formed by homological re-
combination of embryonic stem cells. The changed cells were 
implanted into the blastocyst of a mouse of C57BL/6J strain 
which were subsequently implanted into the uterus. The off-
spring was a “chimera” that was next crossbred with a mouse 
Fig. The initial stage of atherogenesis. Low-density lipoprotein 
(LDL) molecules after crossing the endothelial barrier and pene-
trating into the subendothelial space are trapped and oxidized 
there to oxidized LDL (oxLDL), becoming a foreign antigen for the 
organism. Foam cells trap the oxLDL molecules with the use of 
scavenger receptors. The oxLDL molecule is then digested and 
transformed, and is presented to T lymphocyte, initiating the clas-









130 POLSKIE ARCHIWUM MEDYCYNY WEWNĘTRZNEJ 2008; 118 (3)
REVIEW ARTICLES
REFERENCES




	 2.	 Scandinavian	 Simvastatin	 Survival	 Study	 Group.	 Randomised	 trial	 of	 cholesterol	














and	 smooth	 muscle	 cells	 in	 the	 human	 atherosclerotic	 plaque.	 Arteriosclerosis.	
1986;	6:	131-138.












atherosclerosis-prone	 sites	 on	 the	 endothelium	 in	 the	 ApoE-deficient	 mouse.	
Arterioscler	Thromb	Vasc	Biol.	1998;	18:	842-851.
14.	 Aiello	RJ,	Bourassa	PA,	Lindsey	S,	et	al.	Monocyte	chemoattractant	protein-1	ac-
celerates	 atherosclerosis	 in	 apolipoprotein	 E-deficient	 mice.	 Arterioscler	 Thromb	
Vasc	Biol.	1999;	19:	1518-1525.
15.	 Ni	W,	Egashira	K,	Kitamoto	S,	et	al.	New	anti-monocyte	chemoattractant	protein-1	









19.	 Welt	FG,	Rogers	SD,	Zhang	X,	et	al.	GP	IIb/IIIa	 inhibition	with	eptifibatide	 lowers	


















































mice	 by	 altering	 lymphocyte	 and	 macrophage	 phenotypes.	 Circ	 Res.	 2002;	 90:	
1064-1071.















47.	 Moghadasian	 MH.	 Experimental	 atherosclerosis:	 a	 historical	 overview.	 Life	 Sci.	
2002;	70:	855-865.











53.	 Capecchi	 MR.	 Generating	 mice	 with	 targeted	 mutations.	 Nature	 Med.	 2001;	 7:	
1086-1090.
54.	 Breslow	JL.	Mouse	models	of	atherosclerosis.	Science.	1996;	272:	685-688.
55.	 Hansson	GK,	Libby	P,	Schonbeck	U,	Yan	ZQ.	Innate	and	adaptive	immunity	in	the	
pathogenesis	of	atherosclerosis.	Circ	Res.	2002;	91:	281-291.
56.	 Steinberg	D.	Atherogenesis	in	perspective:	hypercholesterolemia	and	inflammation	
as	partners	in	crime.	Nat	Med.	2002;	8:	1211-1217.
57.	 Fan	J,	Watanabe	T.	Inflammatory	reaction	in	the	pathogenesis	of	atherosclerosis.	J	
Atheroscler	Thromb.	2003;	10:	63-71.
58.	 Libby	P.	Changing	concepts	of	atherogenesis.	J	Intern	Med.	2000;	247:	349-358.
59.	 Libby	P.	Inflammation	in	atherosclerosis.	Nature.	2002;	420:	868-874.
60.	 Libby	P,	Ridker	PM,	Maseri	A.	Inflammation	and	atherosclerosis.	Circulation.	2002;	
105:	1135-1143.
61.	 Jawień	J,	Gajda	M,	Rudling	M,	et	al.	Inhibition	of	five	lipoxygenase	activating	pro-
tein	 (FLAP)	by	MK-886	decreases	atherosclerosis	 in	apoE/LDLR-double	knockout	
mice.	Eur	J	Clin	Invest.	2006;	36:	141-146.	
62.	 Alpert	JS,	Thygesen	K.	A	new	global	definition	of	myocardial	infarction	for	the	21st	
century.	Pol	Arch	Med	Wewn.	2007;	117:	485-486.
